<DOC>
	<DOCNO>NCT00003191</DOCNO>
	<brief_summary>Phase I trial study effectiveness fenretinide treat child solid tumor respond standard therapy . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Fenretinide Treating Children With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose fenretinide ( HPR ) child high risk solid tumor . II . Determine toxicity HPR patient . III . Determine pharmacokinetics HPR patient . IV . Determine CSF level HPR patient cerebrospinal fluid obtain routine purpose study . V. Determine effect HPR plasma retinol level patient . VI . Determine activity HPR patient . VII . Determine antitumor activity HPR minimal residual bone marrow disease neuroblastoma . OUTLINE : This dose escalation study . Patients receive oral fenretinide 3 time day day 1-7 . Treatment repeat every 3 week 8 course . Patients may receive additional 22 course therapy presence stable respond residual tumor . Patients recurrent neuroblastoma , prior myeloablative therapy measurable disease , stop treatment 8 course . Cohorts 3-6 patient receive escalate dos fenretinide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow death .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor refractory conventional therapy recurrent neuroblastoma treat myeloablative therapy autologous stem cell transplant second complete partial response Bone marrow metastasis granulocytopenia , anemia , and/or thrombocytopenia eligible PATIENT CHARACTERISTICS : Age : Under 21 diagnosis Performance status : CCG 02 Life expectancy : At least 2 month Absolute neutrophil count least 750/mm3 Platelet count least 50,000/mm3 Hemoglobin least 7.0 g/dL Bilirubin great 1.5 mg/dL SGOT SGPT less 2.5 time normal Creatinine great 1.5 g/dL OR creatinine clearance least 50 mL/min OR radioisotope GFR least 50 mL/min Seizure disorder control anticonvulsant allow No CNS toxicity great grade 2 Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 1 month since prior autologous stem cell transplantation No prior allogeneic transplantation At least 2 week since prior chemotherapy ( 4 week nitrosourea ) recover No concurrent chemotherapy No concurrent immunomodulating agent ( include steroid ) Concurrent corticosteroid therapy increase intracranial pressure allow Concurrent dexamethasone CNS tumor allow At least 2 week since prior radiotherapy Concurrent radiotherapy localize lesion allow At least 2 week since prior retinoids Prior isotretinoin 9cisretinoic acid allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>